INMB — Inmune Bio Balance Sheet
0.000.00%
- $53.44m
- $25.70m
- $0.01m
Annual balance sheet for Inmune Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 22 | 74.8 | 52.2 | 35.8 | 20.9 |
| Net Total Receivables | 1.8 | 5.5 | 8.46 | 2.44 | 1.41 |
| Prepaid Expenses | |||||
| Total Current Assets | 24 | 82.6 | 64.7 | 39.9 | 22.7 |
| Net Property, Plant And Equipment | 0.156 | 0.726 | 0.507 | 0.414 | 0.307 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 40.7 | 99.9 | 81.8 | 57 | 39.6 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.78 | 4.36 | 10.9 | 18.5 | 7.22 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.9 | 19.7 | 21.7 | 18.9 | 7.46 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 38.8 | 80.2 | 60.1 | 38.1 | 32.1 |
| Total Liabilities & Shareholders' Equity | 40.7 | 99.9 | 81.8 | 57 | 39.6 |
| Total Common Shares Outstanding |